ATE437239T1 - Induktion der mitochondrialen permeabilitätstransition - Google Patents

Induktion der mitochondrialen permeabilitätstransition

Info

Publication number
ATE437239T1
ATE437239T1 AT03810339T AT03810339T ATE437239T1 AT E437239 T1 ATE437239 T1 AT E437239T1 AT 03810339 T AT03810339 T AT 03810339T AT 03810339 T AT03810339 T AT 03810339T AT E437239 T1 ATE437239 T1 AT E437239T1
Authority
AT
Austria
Prior art keywords
compound
permeability transition
mitochondrial permeability
induction
mpt
Prior art date
Application number
AT03810339T
Other languages
English (en)
Inventor
Philip Hogg
Original Assignee
Newsouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002952526A external-priority patent/AU2002952526A0/en
Priority claimed from AU2003906109A external-priority patent/AU2003906109A0/en
Application filed by Newsouth Innovations Pty Ltd filed Critical Newsouth Innovations Pty Ltd
Application granted granted Critical
Publication of ATE437239T1 publication Critical patent/ATE437239T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/06—Aluminium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/74—Aromatic compounds
    • C07F9/78—Aromatic compounds containing amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/80—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/80—Heterocyclic compounds
    • C07F9/82—Arsenic compounds containing one or more pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
AT03810339T 2002-11-07 2003-11-07 Induktion der mitochondrialen permeabilitätstransition ATE437239T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952526A AU2002952526A0 (en) 2002-11-07 2002-11-07 Induction of the mitochondrial permeability transition
AU2003906109A AU2003906109A0 (en) 2003-11-05 A Substantially Cell Membrane Impermeable Arsenoxide Compound and Use Thereof
PCT/AU2003/001483 WO2004042079A1 (en) 2002-11-07 2003-11-07 Induction of the mitochondrial permeability transition

Publications (1)

Publication Number Publication Date
ATE437239T1 true ATE437239T1 (de) 2009-08-15

Family

ID=32313402

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03810339T ATE437239T1 (de) 2002-11-07 2003-11-07 Induktion der mitochondrialen permeabilitätstransition

Country Status (10)

Country Link
US (2) US20060166208A1 (de)
EP (2) EP2088206B1 (de)
JP (1) JP4426456B2 (de)
CN (1) CN101863958B (de)
AT (1) ATE437239T1 (de)
CA (1) CA2504935C (de)
DE (1) DE60328513D1 (de)
ES (1) ES2330519T3 (de)
HK (2) HK1132015A1 (de)
WO (1) WO2004042079A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR874601A0 (en) * 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
WO2003057012A2 (en) 2002-01-07 2003-07-17 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
DE60328513D1 (de) 2002-11-07 2009-09-03 Newsouth Innovations Pty Ltd Induktion der mitochondrialen permeabilitätstransition
JP5486768B2 (ja) * 2005-12-14 2014-05-07 国立大学法人九州大学 細胞内ミトコンドリアの分極モニタリング
EP2069371B1 (de) 2006-11-01 2013-03-13 NewSouth Innovations Pty Limited Organo-arsenoxid-verbindungen und deren verwendung
WO2008058192A2 (en) * 2006-11-08 2008-05-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
WO2009043114A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Arsenoxide compound and method of use
EP2073004A1 (de) * 2007-12-19 2009-06-24 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Elektrophoretische Analyse von isolierten Mitochodrien zum Nachweis von Zell- oder Gewebeschäden
ITRM20120058A1 (it) * 2012-02-20 2013-08-21 Pisanelli Giovanni Codacci Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione
US10113968B2 (en) * 2013-12-03 2018-10-30 The Hong Kong University Of Science And Technology Specific detection and quantification of cardiolipin and isolated mitochondria by positively charged AIE fluorogens and method of manufacturing thereof
JP6468781B2 (ja) * 2014-10-02 2019-02-13 株式会社ヘルスケアシステムズ ミトコンドリア膜透過性の評価方法、ミトコンドリア膜透過性の亢進を抑制する物質のスクリーニング方法、ミトコンドリア膜透過性を亢進する物質のスクリーニング方法、及びミトコンドリア膜透過性の亢進抑制剤
US11819489B2 (en) 2017-10-17 2023-11-21 University Of Wollongong Anti-cancer agent comprising a tumour homing peptide having arsenic bonded to cysteine residues
EP3733197A1 (de) * 2019-04-30 2020-11-04 Stephen N. Pitcher Anaerobe antioxidationszusammensetzung

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2370092A (en) * 1942-05-04 1945-02-20 Parke Davis & Co Organic amine derivatives and method of obtaining same
US2409291A (en) * 1942-05-19 1946-10-15 Squibb & Sons Inc Chemotherapeutic sulfanilamide derivatives
US2465308A (en) * 1946-11-27 1949-03-22 Hoffmann La Roche Arsenoso compounds and method of preparation
US2664432A (en) * 1947-01-28 1953-12-29 Ernst A H Friedheim Heterocyclic metal and sulfur organic compounds
US2553515A (en) * 1948-12-11 1951-05-15 Hoffmann La Roche N-(p-arsenoso-benzyl)-urea
US2951766A (en) * 1957-07-15 1960-09-06 Le Roy A White Antiseptic plastic
BE786573A (fr) 1971-07-20 1973-01-22 Hoechst Ag Medicament a base de composes arsenicaux organiques et de derives du benzimidazole
FR2640269B1 (fr) * 1988-12-13 1991-03-15 Maes Ludo Composes organometalliques, leurs modes de preparation et compositions pharmaceutiques les contenant
US5270196A (en) * 1989-10-20 1993-12-14 Bristol-Myers Squibb Company Arylsulfatase from streptomyces
FR2684382B1 (fr) * 1991-12-02 1994-10-21 Rhone Merieux Medicaments et preparations pures de dichlorhydrate de melarsomine, leur procede d'obtention et produits intermediaires obtenus.
WO1998051297A1 (en) 1997-05-14 1998-11-19 The University Of New Mexico Inhibition of cell surface protein disulfide isomerase
ES2309258T3 (es) 1997-10-15 2008-12-16 Polarx Biopharmaceuticals, Inc. Composiciones farmaceuticas que comprenden trioxido de arsenico para el tratamiento de linfoma no hodgkin.
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
FR2781674B1 (fr) 1998-07-31 2002-06-28 Inst Nat Sante Rech Med Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
IL142895A0 (en) * 1998-11-03 2002-04-21 Mitokor Adenine nucleotide translocator polyptides
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
EP1210596A2 (de) * 1999-06-22 2002-06-05 Mitokor Verfahren zur untersuchung subzellulärer zustände mit hilfe von energietransfer
AUPQ296799A0 (en) * 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
AUPR598901A0 (en) 2001-06-28 2001-07-19 Unisearch Limited Inhibition of angiogenesis by targeting protein tyrosine phosphatases
AUPR874601A0 (en) 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
DE60328513D1 (de) 2002-11-07 2009-09-03 Newsouth Innovations Pty Ltd Induktion der mitochondrialen permeabilitätstransition
EP2069371B1 (de) 2006-11-01 2013-03-13 NewSouth Innovations Pty Limited Organo-arsenoxid-verbindungen und deren verwendung

Also Published As

Publication number Publication date
CA2504935A1 (en) 2004-05-21
EP2088206A2 (de) 2009-08-12
EP1563099B1 (de) 2009-07-22
US20060166208A1 (en) 2006-07-27
ES2330519T3 (es) 2009-12-11
EP1563099A1 (de) 2005-08-17
EP2088206A3 (de) 2009-09-16
CN101863958A (zh) 2010-10-20
HK1132015A1 (en) 2010-02-12
DE60328513D1 (de) 2009-09-03
WO2004042079A1 (en) 2004-05-21
US20140121165A1 (en) 2014-05-01
CN101863958B (zh) 2012-07-18
EP1563099A4 (de) 2008-03-12
US9353152B2 (en) 2016-05-31
HK1073868A1 (en) 2005-10-21
CA2504935C (en) 2012-04-10
JP4426456B2 (ja) 2010-03-03
EP2088206B1 (de) 2013-07-03
JP2006518986A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
HK1073868A1 (en) Induction of the mitochondrial permeability transition
GB0617429D0 (en) Markers of renal transplant rejection and renal damage
HK1152378A1 (en) Labeled cells for use as an internal functional control in rare cell detection assays
ATE419388T1 (de) Nukleinsäureanreicherung
ATE519863T1 (de) Nicht-fluoreszente energieübertragung
WO2007035633A3 (en) Screening assays and methods
CY1111098T1 (el) Bodipy διαιθυλοακεταλη αμινοακεταλδεϋδης
TW200720441A (en) New labelling strategies for the sensitive detection of analytes
MX336070B (es) Eventos de alfalfa tolerantes a glifosato y metodos para su deteccion.
WO2007008759A3 (en) Methods for detecting and confirming minimal disease in a cancer patient
WO2006131599A3 (en) Method of profiling a cell population
DE69737126D1 (de) Hbv mutanten und methoden für deren nachweis
DE60140120D1 (de) Toxizitätstypisierung unter verwendung von leberstammzellen
MX2007012486A (es) Ensayos de investigacion sobre estilbazio.
DK1842920T4 (da) Celler der co-udtrykker K-vitaminreduktase og K-vitaminafhængigt protein, samt anvendelse deraf til at forbedre produktiviteten af det K-vitaminafhængige protein
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
ATE316531T1 (de) Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
ATE294392T1 (de) Reagenz zur bestimmung von blutplättchen- mikroteilchen
ATE473273T1 (de) Angereicherte zellpopulationen des zentralen nervensystems
WO2006079334A3 (de) Verfahren zu nachweis und quantifizierung von proteinen unter verwendung von farbstoffen auf der basis von polymethinen
WO2007021757A3 (en) Fluorescent sensor and methods
DE60332479D1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
EP1308730A4 (de) Verfahren zum nachweis oder zum bestimmen von hbv
ATE336582T1 (de) Polyketid-synthasen mit veränderter spezifität, ihre herstellung und verwendung
WO2006039367A3 (en) Resonance energy transfer system and method

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties